Get started
Author

Kazuyo Sasaki

Observed names: KAZUYO SASAKI, Sasaki, Kazuyo
ORCID: 0000-0001-5267-8284
Observed ORCID: 0000-0001-5267-8284
OpenAlex ID: A5058512882
Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials
2017 · Yuya Seko, Yoshio Sumida, et al. · Journal of Gastroenterology · 71
PDF
Inositol-1,4,5-trisphosphate accumulation induced by urinary pheromones in female rat vomeronasal epithelium
1999 · Kazuyo Sasaki, Kiyoko Okamoto, et al. · Brain Research · 38
Safety and efficacy of canagliflozin in elderly patients with type 2 diabetes mellitus: a 1-year post-marketing surveillance in Japan
2017 · Maki Goda, Tomoko Yamakura, et al. · Current Medical Research and Opinion · 31
PDF
Combined effect of canagliflozin and exercise training on high-fat diet-fed mice
2020 · Kenichi Tanaka, Hirokazu Takahashi, et al. · American Journal of Physiology-Endocrinology and Metabolism · 26
Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan
2019 · Takashi Kadowaki, Masakazu Haneda, et al. · Advances in Therapy · 25
PDF
Novel Zn2+ Modulated GPR39 Receptor Agonists Do Not Drive Acute Insulin Secretion in Rodents
2015 · Ola Fjellström, Niklas Larsson, et al. · PLoS ONE · 25
PDF
Canagliflozin potentiates GLP-1 secretion and lowers the peak of GIP secretion in rats fed a high-fat high-sucrose diet
2017 · Tohru Hira, Toshiki Koga, et al. · Biochemical and Biophysical Research Communications · 20
PDF
Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance
2021 · Nobuya Inagaki, Masaomi Nangaku, et al. · Advances in Therapy · 15
PDF
Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
2018 · Masakazu Haneda, Takashi Kadowaki, et al. · Diabetes Therapy · 14
PDF
Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus
2017 · Takashi Kadowaki, Masakazu Haneda, et al. · Expert Opinion on Pharmacotherapy · 13
PDF
Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
2020 · Takashi Kadowaki, Masakazu Haneda, et al. · Advances in Therapy · 11
PDF
Concentration and Membrane Fluidity Dependence of Odor Discrimination in the Turtle Olfactory System
1997 · Makoto Kashiwayanagi, Kazuyo Sasaki, et al. · Chemical Senses · 11
Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies
2024 · Masaomi Nangaku, Kiichiro Ueta, et al. · Clinical and Experimental Nephrology · 10
PDF
Efficacy and Safety of Teneligliptin 40 mg in Type 2 Diabetes: A Pooled Analysis of Two Phase III Clinical Studies
2018 · Takashi Kadowaki, Kazuyo Sasaki, et al. · Diabetes Therapy · 8
PDF
Real-World Safety and Effectiveness of Vadadustat in Patients with Chronic Kidney Disease-Related Anemia: Interim Analysis of Postmarketing Surveillance in Japan
2025 · Masaomi Nangaku, Kazuyo Sasaki, et al. · Advances in Therapy · 5
PDF
Effectiveness of a Lifestyle Improvement Support App in Combination with a Wearable Device in Japanese People with Type 2 Diabetes Mellitus: STEP-DM Study
2024 · Akiko Takahashi, Manabu Ishii, et al. · Diabetes Therapy · 5
PDF
Relationship of Eating Patterns and Metabolic Parameters, and Teneligliptin Treatment: Interim Results from Post-marketing Surveillance in Japanese Type 2 Diabetes Patients
2018 · Takashi Kadowaki, Masakazu Haneda, et al. · Advances in Therapy · 5
PDF
Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan
2022 · Takashi Kadowaki, Nobuya Inagaki, et al. · Advances in Therapy · 1
PDF
SAT-358-Sodium glucose cotransporter 2 inhibitor, canagliflozin ameliorate liver function in Japanese patients with type 2 diabetes mellitus: Subgroup analyses of clinical trials
2019 · Yuya Seko, Yoshio Sumida, et al. · Journal of Hepatology · 1
2 型糖尿病患者を対象としたジペプチジルペプチダーゼ—4 阻害薬テネリグリプチンの単独療法および糖尿病治療薬との併用療法における安全性と有効性―特定使用成績調査（ruby）の中間報告―
2018 · Takashi Kadowaki, Masakazu Haneda, et al. · 薬理と治療 · 1
Real-World Evidence of Vadadustat in Patients with Anemia and CKD: Interim Results from Postmarketing Surveillance (VIOLET Survey) in Japan
2024 · Kiichiro Ueta, Kenichi Nishimura, et al. · Journal of the American Society of Nephrology
34-LB: Effectiveness of Combination Use of a Lifestyle Improvement Support App and a Wearable Device on Glycemic Control in Japanese People with T2DM—STEP-DM
2023 · AKIKO TAKAHASHI, MANABU ISHII, et al. · Diabetes
実臨床下におけるカナグリフロジンの安全性および有効性~長期使用に関する特定使用成績調査sapphire中間報告 第3報~
2019 · Kyoko Kato, Inagaki Nobuya, et al. · Tōnyōbyō/Tounyoubyou
高齢2型糖尿病患者におけるカナグリフロジンの安全性及び有効性~長期使用に関する特定使用成績調査(sapphire)中間報告 第3報~
2019 · Oi Mariko, Inagaki Nobuya, et al. · Tōnyōbyō/Tounyoubyou
Combination of Canagliflozin and Exercise Training Leads to Lipid-Dependent Energy Expenditure in Skeletal Muscle in Obese Diabetic Mice
2018 · KENICHI TANAKA, HIROKAZU TAKAHASHI, et al. · Diabetes
Works count: 29
Citation count: 336
H-index: 11
I10-index: 13
Year
Topic
Type